Chimeric Therapeutics (ASX:CHM) has announced a collaboration with Melbourne-based Cell Therapies to explore the potential of manufacturing its investigative CAR-T candidates.
Cell Therapies is a commercial contract development and manufacturing company specialising in cell therapy, gene therapy, regenerative medicine, and cellular immunotherapy products.
Its facilities are co-located with the Peter MacCallum Cancer Centre in Melbourne’s Parkville Precinct and are Australia’s only biomedical manufacturing facility where CAR T-cells and other 'living' cancer therapies can be made at a commercial scale.
Chimeric has four Phase 1/1b trials open across the US and is exploring adding new sites in Australia.
“This is great progress for Chimeric and aims to provide Australian patients with access to our first in class CAR T clinical trials,” said Dr Rebecca McQualter, Chimeric's chief operating officer.
“We are very pleased to work with Chimeric to bring their innovative CAR T products to Australian cancer patients in need,” said Dr Bev Menner, CEO of Cell Therapies.